Patient groups influenced by drug company funding, study finds
Action is needed to safeguard the independence of patient organisations and charities, according to the findings of a new study.
The study by the University of Bath, UK, Lund University, Sweden and Kozminski University, Poland, concludes that patient organisations and charities across Europe are at risk of aligning their interests with their corporate funders even when this doesn’t benefit their members.
The new research – led by Dr Piotr Ozieranski from the Department of Social and Policy Sciences at Bath – focuses on pharmaceutical industry payments to patient organisations in Poland.
Patient organisations in the US and across Europe are increasingly dependent on funding from drug companies. In Europe, this happens against a backdrop of reduced government funding of patient groups and dwindling funding for the health sector more broadly.
Dr Ozieranski said: “Patient organisations have established themselves as key stakeholders in the health policy domain, playing an important role in raising awareness of diseases and supporting patients with specific diseases. Pharmaceutical companies are eager to fund their work, but this comes with strings attached – these same companies manufacture drugs designed for the very people who have turned to the patient organisation for independent support.”
“Drug companies shape and mould patient organisations over time. This can be concerning as patient organisations should represent the interests of patients, their carers and families, which are not necessarily the same as those of product manufacturers.”
The risk of undue influence
One example of drug companies benefiting from donating funds to patient-advocacy groups was seen in the US between 1996 and 2008 when the National Alliance on Mental Illness (NAMI) received $45 million from pharmaceutical industry giants like Eli Lilly, Pfizer and Bristol-Myers Squibb.
In a 2006 lawsuit, NAMI was accused of lobbying aggressively for the wider use of expensive new antipsychotics, such as Lilly’s Zyprexa, despite evidence suggesting serious side effects, including weight gain, diabetes and metabolic issues.
A US Senate investigation in 2009 highlighted that pharmaceutical funding significantly influenced NAMI’s operations.
Dr Ozieranski and his collaborators, Dr Marta Makowska (from the Kozminski Academy) and Dr Shai Mulinari (from Lund University), propose three core strategies to mitigate the risks of undue influence being exerted on patient groups:
- Create a central shared pool of funding supported by all companies, so patient organisations avoid becoming overly reliant on one, or a small number of, donor corporations to continue their work.
- Follow the example set by Poland, where taxpayers are invited to allocate 1.5% of their income tax to a specific patient organisation, to fund its activities.
- Replace drug company funding with other funding sources whenever possible.
Diana Spencer, Senior Digital Content Editor, DDW
